WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors.

WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors. Abstract Text:

Pharmacological agents that increase cholinergic transmission have considerable use in cognitive disorders and evidence from both human and animal studies suggests that nicotinic acetylcholine receptors (nAChRs) represent an attractive target for treating certain neurological disorders. This investigation aimed to provide an in vivo verification of the in vitro data on WO03/062224, an agonist selective at beta4 subunit-containing nicotinic receptors. The effects of WO03/062224 were tested on wildtype and beta4 nAChR null mice on two behavioural paradigms; locomotor behaviour and instrumental responding for food on a second order schedule. Separate groups of wildtype and beta4 nAChR subunit knockout mice were tested in each paradigm with instrumental responding and forward locomotion being measured. WO03/062224 had a greater effect in the wildtype mice than the beta4 knockout mice in both locomotor activity (unconditioned behaviour) and instrumental responding (conditioned behaviour). In wildtype mice WO03/062224 caused a significant initial depression in locomotor activity followed by a significant increase in activity. The beta4 knockout mice displayed no significant drug-induced alterations in locomotor activity at any time point. In wildtype mice WO03/062224 caused a significant depression in instrumental responding throughout the session at both 3 mg/kg and 10 mg/kg. The beta4 knockout mice only displayed a reduction in initial responding at 10 mg/kg. The present study demonstrated that the effects of WO03/062224 at 3 mg/kg on locomotor activity and instrumental responding are likely occurring through a beta4 nicotinic mechanism. This investigation has shown that at an appropriate dose WO03/062224 is a suitable in vivo probe for the contribution of beta4-containing nAChRs to behaviour and suggests that their involvement is greater than previously recognised.

WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Pharmacology, biochemistry, and behavior

VOLUME: 91

Page Numbers: 9-13

Journal Abbreviation: Pharmacol. Biochem. Behav.

ISSN: 0091-3057

DAY: 13

MONTH: 06

YEAR: 2008

WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 367050

WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors.

AFFILIATION: Department of Psychology, University of Sussex, Brighton, BN1 9QG, UK.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pharmacol Biochem Behav

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors Related Publications

• Appetite hormones and energy intake in obese men after consumption of fructose, glucose and whey protein beverages.
• Back diffusion of hydrogen ions across gastric mucosa of patients with gastric ulcer and rheumatoid arthritis.
• Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes.
• Effect of intragastric bile salts on ionic movement across normal human gastric mucosa after intravenous atropine.
• Effects of weight loss from a very-low-carbohydrate diet on endothelial function and markers of cardiovascular disease risk in subjects with abdominal obesity.
• Effects of weight loss on a low-carbohydrate diet on flow-mediated dilatation, adhesion molecules and adiponectin.
• Follow-up of a case of tuberculosis of the medical malleolus of the right tibia.
• Good agreement between bioelectrical impedance and dual-energy X-ray absorptiometry for estimating changes in body composition during weight loss in overweight young women.
• Growth and assimilation in cultures of Saccharomyces cerevisiae.
• HYPOTENSION ASSOCIATED WITH TETANUS.
• High dairy-protein versus high mixed-protein energy restricted diets - the effect on bone turnover and calcium excretion in overweight adults.
• Hormones and experimental oncogenesis: mammary and mammotropic tumors.
• How tough is bone? Application of elastic-plastic fracture mechanics to bone.
• Low- and high-carbohydrate weight-loss diets have similar effects on mood but not cognitive performance.
• Male sex and pre-existing diabetes are independent risk factors for stillbirth.
• Mammalian plasma membrane proteomics.
• Maternal and cord plasma cytokine and chemokine profile in pregnancies complicated by asthma.
• Maternal asthma and placental morphometry: effects of severity, treatment and fetal sex.
• Metabolic effects of weight loss on a very-low-carbohydrate diet compared with an isocaloric high-carbohydrate diet in abdominally obese subjects.
• Reductions in blood pressure following energy restriction for weight loss do not rebound after re-establishment of energy balance in overweight and obese subjects.
• The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control.
• The effect of meal replacements high in glycomacropeptide on weight loss and markers of cardiovascular disease risk.
• The effect of milk protein on the bioavailability of cocoa polyphenols.
• The effect of protein source (dairy vs mixed) in high protein, energy restricted diets on body composition, vascular health and metabolic markers in overweight adults.
• Use of monolithic supports in proteomics technology.
• WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors.
• Whey protein isolate and glycomacropeptide decrease weight gain and alter body composition in male Wistar rats.